Galeterone

Galeterone (pronounced gah-LEH-teh-rone) is a pharmaceutical drug used in the treatment of prostate cancer. It is an androgen receptor antagonist and CYP17A1 inhibitor.

Etymology

The term "Galeterone" is derived from the name of the company that first developed the drug, Galeria Pharmaceuticals, and the terone suffix common to many steroid drugs.

Pharmacology

Galeterone works by inhibiting the enzyme CYP17A1, which is involved in the production of androgens in the body. By blocking this enzyme, Galeterone reduces the amount of androgens available to stimulate the growth of prostate cancer cells. Additionally, Galeterone also acts as an antagonist at the androgen receptor, further preventing the growth of prostate cancer cells.

Clinical Use

Galeterone is used in the treatment of prostate cancer, particularly in cases where the cancer has become resistant to other forms of androgen deprivation therapy. It is typically used in combination with other drugs as part of a comprehensive treatment plan.

Related Terms

• Androgen deprivation therapy
• CYP17A1
• Androgen receptor
• Prostate cancer
• Pharmaceutical drug
• Steroid

External links

• Medical encyclopedia article on Galeterone
• Wikipedia's article - Galeterone

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski